^
BIOMARKER:

Chr del(11q)

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Chr del(11q)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive
:
B
SOHO 2022 - 1 week - (New B)
Chr del(11q)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
B
SOHO 2022 - 1 week - (New B)
Chr del(11q)
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive
:
A2
Chr del(11q)
Chronic Lymphocytic Leukemia
rituximab
Resistant
:
A2
Chr del(11q)
Chronic Lymphocytic Leukemia
obinutuzumab + acalabrutinib
Sensitive
:
A2
Chr del(11q)
Chronic Lymphocytic Leukemia
ibrutinib + ublituximab
Sensitive
:
B
Chr del(11q)
Chronic Lymphocytic Leukemia
obinutuzumab
Resistant
:
B
Chr del(11q)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
B
Chr del(11q)
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive
:
B
Chr del(11q)
Chronic Lymphocytic Leukemia
venetoclax
Sensitive
:
C2
Chr del(11q)
Chronic Lymphocytic Leukemia
lenalidomide + tafasitamab
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
RP6530
Sensitive
:
C3
Chr del(11q)
Small Lymphocytic Lymphoma
orelabrutinib
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
orelabrutinib
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
venetoclax + ibrutinib
Sensitive
:
C3
Chr del(11q)
Multiple Myeloma
obinutuzumab
Resistant
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
duvelisib
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
FCR
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
ibrutinib + UC-961
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Compound C
Sensitive
:
D
Chr del(11q)
Chronic Lymphocytic Leukemia
hydroxychloroquine
Sensitive
:
D
Chr del(11q)
Chronic Lymphocytic Leukemia
MRT68921
Sensitive
:
D